Cowen assumed coverage on shares of Personalis (NASDAQ:PSNL) in a research note published on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating on the stock.
Other analysts also recently issued research reports about the company. Morgan Stanley set a $70.00 price objective on Edison International and gave the stock a hold rating in a research note on Monday. Bank of America set a $68.00 price objective on Inphi and gave the stock a buy rating in a research note on Monday. Finally, Oppenheimer set a $110.00 price objective on Medtronic and gave the stock a buy rating in a research note on Monday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Personalis presently has a consensus rating of Buy and an average price target of $28.25.
NASDAQ:PSNL opened at $21.40 on Monday. Personalis has a 1 year low of $20.21 and a 1 year high of $31.88.
In other news, Director Ken Ludlum acquired 70,000 shares of Personalis stock in a transaction on Monday, June 24th. The shares were acquired at an average price of $17.00 per share, with a total value of $1,190,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Personalis Company Profile
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Featured Story: Market Perform
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.